Spotlight on Imatinib Mesylate in Chronic Myeloid Leukemia
Purchase on Springer.com
$49.95 / €39.95 / £34.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Imatinib mesylate (Gleevec®, Glivec®) is an orally administered competitive inhibitor of the BCR-ABL tyrosine kinase created by the Philadelphia chromosome (Ph+) in chronic myeloid leukemia (CML).
In patients with newly diagnosed and previously untreated (apart from hydroxyurea and/or anagrelide) CML in the chronic phase, imatinib mesylate 400 mg/day, compared with interferon-α (IFNα) plus cytarabine, resulted in higher hematologic response (HR) and cytogenetic response (CR) rates and fewer patients progressing to the accelerated phase or blast crisis in a large comparative trial. Preliminary results indicate that, compared with IFNα plus cytarabine, imatinib mesylate treatment was associated with similar total costs, but resulted in a higher health-related quality of life (HR-QOL).
Imatinib mesylate was also effective in patients with chronic-phase CML refractory to or intolerant of treatment with IFNα (as 400 mg/day) and in those with blast-crisis or accelerated-phase CML (600 mg/day). In the latter groups, HR and CR rates were lower than those in patients with chronic-phase CML.
Imatinib mesylate-associated adverse events were common in clinical trials, but were mostly mild to moderate in severity. The most frequently reported adverse events were superficial edema, nausea, muscle cramps, diarrhea, vomiting, and skin rash. Myelosuppression (thrombocytopenia and neutropenia) was also reported, especially in patients with advanced disease. In patients with previously untreated chronic-phase CML, serious adverse events (both hematologic and nonhematologic) were less common with imatinib mesylate than with IFNα plus cytarabine treatment.
Conclusion: Imatinib mesylate is a valuable therapy for patients with newly diagnosed Ph+ chronic-phase CML. It is better tolerated and produces higher HR, CR and freedom from progressive disease rates than conventional therapy with IFNα plus cytarabine. Preliminary results indicate that, compared with IFNα plus cytarabine, imatinib mesylate treatment was associated with similar total costs, but resulted in a higher HR-QOL. Imatinib mesylate is also effective in patients with accelerated-phase and blast-crisis CML, and patients with chronic-phase CML who have failed IFNα therapy. Given its efficacy and generally manageable adverse event profile, imatinib mesylate offers an important early treatment option for patients with CML.
- Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996 May; 2: 561–6 CrossRef
- Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997 Dec 15; 90: 4947–52
- Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000 Oct; 295(1): 139–45
- Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997; 23(19): 380–94 CrossRef
- Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997 Nov 1; 90(9): 3691–8
- Beran M, Cao X, Estrov Z, et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing 190-KD BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Blood 1997 Nov 15; 90Suppl. 1. Pt 1: 248a
- le Coutre P, Mologni L, Cleris L, et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999 Jan 20; 91(2): 163–8 CrossRef
- Kawaguchi Y, Jinnai I, Nagai K, et al. Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells. Leukemia 2001 Apr; 15: 590–4 CrossRef
- Topaly J, Zeller WJ, Fruehauf S. Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. Br J Haematol 2002 Oct; 119(1): 3–14 CrossRef
- le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000 Mar 1; 95: 1758–66
- Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75–85 CrossRef
- Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001 Aug 3; 293(5531): 876–80 CrossRef
- Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002 May 1; 99(9): 3472–5 CrossRef
- von Bubnoff N, Schneller F, Peschel C, et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002 Feb 9; 359: 487–91 CrossRef
- Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002 Aug; 2(2): 117–25 CrossRef
- Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–6 CrossRef
- Novartis Pharmaceuticals Corporation. Gleevec™ imatinib mesylate: full prescribing information. East Hanover (NJ): Novartis, 2002 Feb
- Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001 Apr 5; 344(14): 1031–7 CrossRef
- O’Brien SG, Peng B, Dutreix C, et al. A pharmacokinetic interaction of Glivec® and simvastatin, a cytochrome 3A4 substrate, in patients with chronic myeloid leukemia [abstract no. 593]. Blood 2001; 98 (11 Pt 1): 141a
- O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348(11): 994–1004 CrossRef
- Lange T, Niederwieser DW. Residual disease in chronic myeloid leukemia after induction of molecular remission. N Eng J Med 2003; 349(15): 1483–4 CrossRef
- Hahn EA, Sorensen MV, Hudgens SA, et al. Quality of life of patients with chronic phase chronic myeloid leukemia in the IRIS Study of interferon-alpha plus Ara-C vs imatinib (STI571, Glivec®, Gleevec™[abstract no. 346]. Blood 2002 Nov 16; 100 (Pt 1): 94a
- Reed SD, Radeva JI, Glendenning A, et al. Within-trial resource utilization and costs of patients randomized to treatment with imatinib (STI571) versus interferon-alpha (IFN-α) combined with cytarabine (Ara-C) in newly diagnosed patients with chronic myeloid leukemia in chronic phase [abstract no. 698]. Blood 2002 Nov 16; 100 (Pt 1): 187a
- Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002 Feb 28; 346(9): 645–52 CrossRef
- Hensley ML, Van Hoomissen IC, Krahnke T, et al. Imatinib in chronic myeloid leukemia (CML): outcomes in >7000 patients treated on expanded access program (EAP) [abstract no. 2328]. 39th Annual Meeting of the American Society of Clinical Oncology; 2003, May 31–Jun 3; Chicago, 579
- Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002 Mar 15; 99(6): 1928–37 CrossRef
- Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologie and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002 May 15; 99: 3530–9 CrossRef
- Spotlight on Imatinib Mesylate in Chronic Myeloid Leukemia
Volume 18, Issue 3 , pp 207-210
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors